SCHEMBL25124504

SCHEMBL25124504

CCNc1cccc(-n2ccnc2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.54
CYP3A4 P08684 3/20 0.50
ABL1 P00519 2/20 0.47
PDGFRB P09619 1/20 0.47
BCR P11274 1/20 0.47
SRC P12931 1/20 0.47
PDGFRA P16234 1/20 0.47
PRKCA P17252 1/20 0.47
PRKCD Q05655 1/20 0.47
CYP19A1 P11511 2/20 0.46
CYP11B1 P15538 2/20 0.46
CYP11B2 P19099 2/20 0.46
CYP2A6 P11509 1/20 0.46
PDE4A P27815 1/20 0.44
PDE4B Q07343 1/20 0.44
PDE4C Q08493 1/20 0.44
PDE4D Q08499 1/20 0.44
ALDH1A1 P00352 1/20 0.43
MAPT P10636 1/20 0.43
TDP1 Q9NUW8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21646511 0.83 IDO1 (0.58) IDO1CYP3A4ABL1PDGFRBBCR
SCHEMBL1798849 0.82 CYP3A4 (0.55) CYP3A4CYP19A1CYP11B1CYP11B2CYP2A6
SCHEMBL21362368 0.78 CYP3A4 (0.62) IDO1CYP3A4ABL1PDGFRBBCR
SCHEMBL14489499 0.78 IDO1 (0.75) IDO1CYP3A4CYP19A1CYP11B1CYP11B2
SCHEMBL4475935 0.77 IDO1 (0.55) IDO1CYP3A4CYP19A1CYP11B1CYP11B2
SCHEMBL8592858 0.77 ABL1 (0.67) IDO1CYP3A4ABL1PDGFRBBCR
SCHEMBL12017933 0.77 CYP3A4 (0.60) IDO1CYP3A4ABL1PDGFRBBCR
SCHEMBL2643843 0.77 IDO1 (0.55) IDO1CYP3A4ABL1PDGFRBBCR
SCHEMBL4485099 0.76 IDO1 (0.58) IDO1CYP3A4CYP19A1CYP11B1CYP11B2
SCHEMBL8214338 0.76 TAAR1 (0.55) IDO1CYP3A4ABL1PDGFRBBCR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230109839-A1 THERAPEUTIC AGENT FOR TAUOPATHIES Sumitomo Pharma Co., Ltd. (JP) 2023-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230109839-A1 THERAPEUTIC AGENT FOR TAUOPATHIES MAPT, PSEN1, PSEN2 IDO1 4698/4885CYP3A4 4734/4885ABL1 3883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.